recombin
glutathionestransferas
fusion
protein
express
amino
acid
equin
arter
viru
eav
g
test
elisa
abil
detect
serum
antibodi
eav
host
antibodi
induc
follow
eav
infect
hound
recombin
antigen
elisa
elisa
specif
sensit
determin
panel
equin
sera
includ
postinfect
postvaccin
sampl
good
correl
exist
eav
neutral
antibodi
titer
elisa
absorb
valu
r
sensit
specif
elisa
respect
compar
eav
neutral
test
recombin
antigen
crossreact
elisa
equin
sera
direct
common
equin
respiratori
virus
three
posteav
infect
equin
sera
rais
differ
eav
isol
react
strongli
elisa
two
equin
sera
rais
eav
vaccin
indic
viral
epitop
conserv
virus
test
follow
vaccin
inactiv
whole
viru
vaccin
antibodi
detect
recombin
antigen
elisa
preced
develop
virusneutr
respons
studi
demonstr
potenti
applic
diagnost
antigen
correspond
author
fax
el
sevier
scienc
bv
right
reserv
ssdi
virologicul
methodc
equin
viral
arter
eva
date
report
infect
hors
doll
et
al
chirnsid
although
seroposit
donkey
found
paweska
barnard
diseas
known
year
manifest
wide
vari
clinic
sign
sever
form
equin
arter
viru
eav
infect
caus
abort
doll
et
al
foal
death
golnik
et
al
vaala
et
al
although
usual
viru
caus
mild
respiratori
diseas
chirnsid
diseas
outbreak
identifi
infrequ
due
clinic
inappar
infect
field
isol
viru
rare
caus
agent
eav
small
posit
singlestrand
rna
viru
genom
organ
mode
replic
gene
express
strategi
similar
coronaand
torovirus
de
vri
et
al
de
vri
et
al
den
boon
et
al
snijder
et
al
eav
recent
classifi
genu
arteriviru
cavanagh
et
al
along
lactat
dehydrogenaseelev
viru
mice
ldv
godeni
et
al
kuo
et
al
simian
hemorrhag
fever
viru
shfv
plagemann
moennig
viru
caus
porcin
respiratori
reproduct
syndrom
prrsv
conzelmann
et
al
lelystad
viru
lv
meulenberg
et
al
eav
transmit
respiratori
vener
rout
carrier
state
exist
seroposit
stallion
timoney
et
al
make
latter
rout
particular
caus
concern
stallion
shed
viru
semen
may
consequ
infect
broodmar
neu
et
al
eva
geograph
widespread
chirnsid
european
north
american
countri
eavseroposit
anim
outbreak
occur
follow
import
persist
infect
anim
caus
primari
transmiss
eav
vener
rout
follow
secondari
respiratori
spread
wood
et
al
light
potenti
econom
import
diseas
hors
breed
race
industri
requir
exist
prophylact
treatment
reliabl
serodiagnosi
infect
laboratorybas
serolog
test
includ
eav
viru
neutral
test
nt
complement
fixat
cf
enzymelink
immunosorb
assay
elisa
senn
et
al
fukunaga
mccollum
cook
et
al
elisa
rel
low
specif
appli
sera
hors
previous
vaccin
equin
influenza
herpesvirus
primarili
due
host
antibodi
induc
tissu
cultur
contamin
vaccin
react
cell
culturederiv
antigen
present
wholeviru
elisa
antigen
cf
test
limit
tempor
sensit
consequ
use
serodiagnosi
week
postinfect
present
nt
result
design
laboratori
intern
accept
importexport
test
infect
eav
elicit
virusneutr
antibodi
respons
within
day
stallion
previous
expos
eav
therefor
may
shedder
infecti
viru
detect
nt
discern
level
circul
neutral
antibodi
persist
mani
year
recoveri
gerber
et
al
nt
sensit
suffer
disadvantag
requir
laboratori
test
maintain
cell
cultur
stock
infecti
viru
addit
nt
take
sever
day
complet
laboratori
use
vari
test
protocol
differ
reagent
lead
dispar
result
moreov
nt
differenti
host
serolog
respons
induc
vaccin
result
natur
infect
recent
demonstr
neutral
monoclon
antibodi
recogn
determin
larg
envelop
glycoprotein
g
balasuriya
et
al
deregt
et
al
paper
describ
indirect
elisa
use
recombin
glutathionestransferas
fusion
protein
smith
johnson
antigen
screen
equin
sera
presenc
antibodi
eav
evalu
diagnost
test
larg
number
equin
serum
sampl
plasmid
dna
manipul
carri
describ
previous
sambrook
et
al
transform
plasmid
smith
johnson
carri
escherichia
coli
tgl
recombin
clone
select
antibiot
resist
clone
subsequ
screen
fusion
protein
express
iptg
induct
analysi
polyacrylamid
gel
eavspecif
insert
size
orient
infram
insert
confirm
restrict
endonucleas
digest
analysi
dsdna
sequenc
purifi
plasmid
dna
chirnsid
et
al
express
construct
srsal
express
compris
nucleotid
eav
open
read
frame
orf
fuse
infram
carboxylterminu
glutathionestransferas
gene
express
vector
fusion
protein
affin
purifi
use
glutathion
sepharos
pharmacia
cultur
bacteri
cell
express
recombin
antigen
harvest
centrifug
min
g
resuspend
ml
mm
trishcl
ph
mm
edta
mm
nacl
ste
recentrifug
pellet
cell
supernat
discard
cell
resuspend
ml
ste
lysozym
mgml
ad
tube
incub
min
tube
frozen
overnight
follow
short
immers
boil
water
bath
thaw
frozen
suspens
dnase
pg
mgcl
ad
thaw
cell
tube
incub
min
triton
ad
final
concentr
l
mixtur
kept
ice
min
centrifug
g
min
glutathion
sepharos
gel
ad
supernat
solut
mix
gentl
agit
rotari
mixer
min
gel
wash
time
pb
recombin
antigen
elut
gel
reduc
glutathion
mm
glutathion
mm
trishcl
ph
eluat
collect
lml
fraction
analyz
sdspolyacrylamid
gel
electrophoresi
prior
pool
fraction
contain
purifi
protein
pool
protein
dispens
aliquot
frozen
use
protein
concentr
determin
modifi
lowri
reagent
solut
protein
assay
kit
sigma
optim
concentr
reactant
determin
checkerboard
titrat
immulon
microtit
plate
dynatech
coat
gst
fusion
protein
dilut
mm
carbon
buffer
ph
kept
overnight
plate
wash
time
pb
contain
tween
pbst
ul
pbst
contain
goat
serum
pbstg
ad
well
follow
incub
h
wash
pbst
hors
sera
dilut
lo
pbstg
ad
well
plate
incub
min
plate
wash
time
pbst
lo
dilut
affinitypurifi
biotinlabel
goat
antiy
chain
specif
hors
igg
kpl
ad
well
plate
incub
min
plate
wash
time
pbst
dilut
streptavidinperoxidas
kpl
pbstg
ad
well
plate
incub
room
temperatur
min
final
wash
pbst
substrat
solut
mg
ml
ophenylenediamin
dihydrochlorid
dissolv
mm
phosphatecitr
buffer
ph
contain
sodium
perbor
ad
well
plate
incub
room
temperatur
min
reaction
stop
addit
h
well
absorb
read
nm
serum
sampl
assay
duplic
well
purifi
gst
fusion
protein
mean
absorb
valu
taken
read
antigen
elisa
valid
inclus
ntelisam
control
sera
mean
absorb
valu
control
sera
individu
elisa
test
grand
assay
mean
test
addit
ntelisa
control
sera
also
run
standard
test
confirm
sensit
assay
immunoblot
carri
equin
sera
dilut
use
modifi
version
elisa
protocol
electrophoret
transfer
protein
sdspolyacrylamid
gel
onto
nitrocellulos
membran
nonspecif
bind
equin
antibodi
nitrocellulos
membran
first
block
overnight
incub
pbstg
membran
wash
time
pbst
elisa
protocol
bind
wash
compon
antibodi
sandwich
perform
wash
min
step
develop
signal
immunoblot
ecl
detect
system
amersham
employ
use
manufactur
protocol
eav
neutral
test
carri
accord
method
senn
et
al
minor
modif
sera
initi
screen
dilut
replic
well
microtit
plate
viru
neutral
sera
subsequ
titrat
replic
well
initi
dilut
individu
nt
includ
posit
control
sera
viru
control
ensur
lootcid
bucyru
strain
eav
ad
well
seri
cell
control
individu
well
score
cytopath
effect
cpe
h
incub
co
titer
calcul
accord
formula
karber
serum
consid
seroposit
nt
titer
log
rise
titer
regard
seroconvers
follow
viru
infect
vaccin
throughout
studi
batch
bucyru
strain
eav
guinea
pig
complement
use
cell
use
passag
number
ensur
excel
compar
eav
neutral
test
field
sera
use
studi
submit
diagnost
servic
anim
health
trust
viru
typespecif
sera
provid
dr
yoshio
fukunaga
equin
research
institut
japan
panel
european
american
sera
obtain
dr
margaret
luca
central
veterinari
laboratori
uk
fusion
protein
deriv
eav
g
shown
react
postinfect
eav
neutral
hors
sera
chirnsid
et
al
glutathionestransferas
fusion
protein
express
plasmid
construct
contain
amino
acid
residu
eav
g
deriv
bucyru
isol
fusion
protein
rg
express
high
level
iptginduc
cell
purifi
readili
affin
chromatographi
glutathion
sepharos
purifi
contain
contamin
bacteri
protein
fig
la
immunoblot
equin
sera
fig
lbd
strongli
recogn
eav
neutral
sera
fig
lb
faintli
antiserum
gst
fig
id
slightli
nonneutr
equin
serum
test
fig
lc
purifi
gst
recogn
equin
sera
rais
specif
gst
also
viru
neutral
nonneutr
equin
sera
optim
antigen
antibodi
concentr
elisa
determin
checkerboard
titrat
serum
dilut
antigen
concentr
pg
per
well
select
give
maximum
discrimin
nt
ntsera
major
equin
sera
reactiv
gst
absorb
rang
reagent
concentr
consequ
absorb
valu
gst
subtract
absorb
valu
recombin
protein
give
eavspecif
figur
test
sampl
equin
sera
rais
specif
equin
herpesviru
type
equin
rhinoviru
type
equin
adenoviru
recogn
elisa
recombin
antigen
bound
eav
neutral
equin
sera
order
evalu
potenti
antigen
diagnost
elisa
compar
result
directli
eav
neutral
test
elisa
absorb
equin
sera
compar
nt
titer
fig
data
plot
fig
intercept
plu
two
standard
deviat
determin
linear
regress
analysi
fig
taken
cutoff
point
determin
elisa
seroposit
valu
tabl
show
numer
breakdown
result
use
seropositiveseroneg
cutoff
valu
viru
neutral
sera
clearli
distinguish
elisa
sampl
seroneg
nt
elisa
sensit
detect
nt
seroposit
detect
one
virusneutr
sampl
low
antibodi
titer
log
elisa
specif
elisa
detect
nt
seroneg
sampl
correctli
detect
due
detect
sampl
absorb
read
neg
nt
log
ntelisa
group
includ
blood
sampl
hors
held
equin
premis
affect
eav
outbreak
england
wood
et
al
diagnost
sampl
assort
hors
submit
serolog
screen
includ
eav
nt
blood
sampl
hors
previous
vaccin
either
one
two
dose
inactiv
eav
vaccin
anomal
equin
sera
subject
investig
repeat
nt
repeat
elisa
fresh
batch
elisa
ntsampl
elisa
eavspecif
antigen
number
compris
serum
sampl
vaccin
hors
outbreakassoci
anim
two
sera
submit
gener
serodiagnosi
pair
sera
origin
hors
cours
uk
eav
outbreak
wood
et
al
seroconvert
nt
elisa
test
nt
elisato
ntelisa
pair
sera
hors
associ
eav
outbreak
seroconvert
either
diagnost
test
pair
sera
hors
test
nt
elisa
prior
week
administr
two
dose
inactiv
eav
vaccin
among
vaccine
ntelisa
ntelisa
elisa
antibodi
respons
detect
absenc
vaccineinduc
neutral
antibodi
possibl
effect
variat
g
virus
investig
compar
elisa
absorb
read
nt
titer
two
post
vaccin
sera
rais
live
kill
vaccin
deriv
bucyru
strain
postinfect
eav
isol
specif
equin
sera
fig
although
differ
absorb
valu
evid
sera
posit
elisa
homolog
sera
deriv
infect
bucyru
isol
bucyru
vaccin
inactiv
viru
kill
bucyru
higher
absorb
valu
equin
sera
rais
heterolog
viru
isol
live
attenu
vaccin
arvac
fort
dodg
laboratori
although
littl
variat
nt
antibodi
titer
bucyru
isol
eav
recombin
antigen
deriv
detect
isol
evalu
util
two
panel
equin
sera
assay
elisa
panel
one
european
one
american
origin
compris
mixtur
postinfect
eavneg
sera
use
refer
sera
monitor
standard
viru
neutral
test
laboratori
unpublish
two
serum
panel
tabl
elisa
sensit
specif
nt
sera
test
elisa
ntsera
test
elisaand
ntsera
test
elba
serolog
reactiv
recombin
eav
g
fusion
protein
report
use
describ
detect
equin
antibodi
eav
elisa
assay
prove
highli
sensit
specif
detect
eav
antibodi
correl
well
result
eav
microneutr
test
detect
postinfect
seroconvers
hors
follow
natur
infect
vaccin
elisa
field
sera
dilut
react
gst
caus
variabl
background
absorb
oo
possibl
reduc
background
absorb
cleav
gst
moieti
g
fusion
protein
clone
eav
differ
express
vector
howev
present
format
correl
elisa
nt
high
r
elba
detect
addit
seroposit
nt
elisa
nt
result
could
due
differ
sensit
two
test
elisa
detect
equin
antibodi
bind
eav
g
capabl
neutral
viru
nt
subpopul
altern
detect
elisantsampl
includ
vaccin
hors
pose
question
specif
elisa
biolog
relev
compar
nt
howev
follow
one
two
dose
inactiv
vaccin
possibl
demonstr
elisantresult
vaccine
similar
situat
exist
follow
natur
infect
eav
addit
seroposit
field
sampl
detect
elisa
may
origin
hors
previous
infect
eav
viru
neutral
antibodi
respons
induc
respons
drop
detect
level
observ
requir
investig
sinc
presenc
circul
viru
neutral
antibodi
date
accept
evid
prior
exposur
eav
either
infect
vaccin
elisa
result
suggest
may
case
membran
topolog
eav
g
remain
establish
howev
hydropathi
profil
de
vri
et
al
posit
sole
nglycosyl
site
den
boon
et
al
determin
protein
ectodomain
like
encompass
residu
test
equin
sera
elisa
demonstr
amino
acid
residu
bucyru
strain
eav
g
encompass
highli
immunoreact
antigen
correl
close
host
viru
neutral
respons
eav
g
shown
contain
major
antigen
site
chirnsid
et
al
viru
neutral
murin
monoclon
antibodi
react
protein
molecular
size
kda
equival
g
western
blot
balasuriya
et
al
deregt
et
al
eav
strain
variat
demonstr
nucleotid
level
rnase
tl
fingerprint
murphi
et
al
murphi
et
al
direct
sequenc
eav
nand
mgene
chirnsid
et
al
antigen
variat
infer
crossneutr
studi
fukunaga
et
al
equin
immun
respons
eav
induc
differ
eav
isol
detect
elisa
deriv
bucyru
isol
impli
high
degre
conserv
epitop
substanti
find
sequenc
studi
eav
g
differ
isol
current
undertaken
chang
relianc
sole
nt
initi
rapid
screen
elisa
follow
neutral
antibodi
test
elisa
sampl
would
improv
speed
diagnosi
eav
seroneg
hors
lower
cost
initi
test
potenti
erad
differ
test
result
laboratori
addit
enhanc
detect
seroposit
anim
alli
vaccin
polici
select
breed
practic
would
allow
better
control
possibl
erad
eav
breed
popul
express
purif
simpl
elisa
easili
standard
differ
test
laboratori
sinc
recombin
protein
infecti
afford
opportun
undertak
eav
serodiagnost
assay
rapidli
safe
without
viru
contain
facil
addit
use
purifi
protein
express
bacteri
system
remov
problem
nonspecif
antibodi
crossreact
cell
culturederiv
antigen
plagu
previou
eav
elisa
test
cook
et
al
